Halozyme Therapeutics (Halozyme Therapeutics) Net Cash per Share : $-10.36 (As of Dec. 2023)

Halozyme Therapeutics Net Cash per Share Chart

Halozyme Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Net Cash per Share		Get a 7-Day Free Trial					-0.39	-0.45	-1.21	-9.68	-10.36

Halozyme Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Cash per Share	Get a 7-Day Free Trial															-9.68	-10.31	-9.94	-8.78	-10.36

Competitive Comparison of Halozyme Therapeutics's Net Cash per Share

For the Biotechnology subindustry, Halozyme Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Price-to-Net-Cash falls into.

Halozyme Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Halozyme Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Halozyme Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics  (NAS:HALO) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Halozyme Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (Halozyme Therapeutics) Business Description